author-photo

Alma Katharina Steinbach-Buechert

Merck Serono

3

Papers

8

Citations

Citation Trend

Filter By

Papers (3) Sort By

Journal Conference Others

Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line (1L) treatment of RAS wild-type (wt) metastatic colorectal cancer (mCRC) in Germany: Data from the FIRE-3 (AIO KRK-0306) study.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Outcome of patients with KRAS exon 2 wildtype (KRAS-wt) metastatic colorectal carcinoma (mCRC) with cetuximab-based first-line treatment in the noninterventional study ERBITAG and impact of comorbidity and age.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (6)
Impact of prophylactic treatments of cetuximab-based skin reactions in patients with metastatic colorectal carcinoma (mCRC): Interim analysis of the German noninterventional study ERBITAG.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)